Egnach, January 21, 2025 – The work for the double-blind study on the tinniwell is now starting. In the first step, the software will be adjusted, and after successful testing, a second clinical observational study with the same design as the double-blind study will be conducted. After successful completion of the work, the final study will be initiated immediately.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG

Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668

a.rauterkus@resaphene.ch